I-Telix Pharmaceuticals Limited namhlanje ibhengeze ukuba isigulana sokuqala senziwe ithamo kuphononongo lwe-'STARLITE 2' yeSigaba sesi-II sonyango lweNkampani yophando lomhlaza wezintso, i-TLX250 (177Lu-DOTA-girentuximab), kwiZiko loMhlaza leSikhumbuzo Sloan Kettering (MSK) eNew York. .
I-STARLITE 2 (i-NCT05239533) iya kuhlola ukusebenza kwe-TLX250 ejoliswe kwi-radiation ngokudibanisa ne-immunotherapy kwi-cell cell renal cell carcinoma (ccRCC), eyona ndlela ixhaphakileyo kunye neyondlongo yomhlaza wezintso. I-TLX250 ijolise kwi-carbonic anhydrase IX (CA9), [1] iprotheyini ebonakaliswa kakhulu kwizigulana ezinokuthi zibonise impendulo elinganiselweyo kunyango lomhlaza. Ingcinga yeyokuba iidosi eziphantsi zemitha ekujoliswe kuyo zinokukoyisa ukuxhathisa amajoni omzimba- okanye "i-immune prime" ithumba kwaye ke ngoko iyenze iphendule ngakumbi kumhlaza wonyango.
Olu phononongo lweSigaba sesi-II, kwizigulane eziye zaqhubela phambili ngokulandela i-immunotherapy yangaphambili, ziya kuvavanya i-TLX250-enikezelwe ngemitha ngokudibanisa ne-anti-PD-1[3] immunotherapy Opdivo®[4] (nivolumab). Isiphelo esiphambili kukumisela ukhuseleko kunye nokusebenza kakuhle kwonyango oludibeneyo kunye ne-TLX250 njengoko ihlolwe ngamathumba aphendula unyango lwe-Telix ngokubhekiselele kumgangatho wangoku wokunyamekela yedwa. I-agent ye-Telix yophando ye-imaging ye-TLX250-CDx (89Zr-DFO-girentuximab) nayo iya kusetyenziswa kwisifundo somfanekiso we-CA9 ibinzana. Uphononongo olukhokelwa ngumphandi wengalo enye kulindeleke ukuba lubhalise malunga nezigulane ezingama-30.
IGosa eliPhezulu lezoNyango likaTelix, uGqr. Colin Hayward uthe, “Ukudityaniswa kweyeza elichanekileyo lenyukliya kunye ne-oncology yonyango kuyaqhubeka kwaye uTelix uphambili kule ntshukumo ukuphuhlisa iimveliso ezizezakho kunye neerejimeni ezilungele isigulane. Sinqwenela ukuvakalisa umbulelo wethu kuGqr. Darren Feldman kunye neqela lakhe lezonyango, kunye nezigulane eziya kuthi zibe negalelo kolu phononongo olusisiseko.
INTO ONOKUYITHATHA KWELI NQAKU:
- The primary endpoint is to determine the safety and efficacy of combination therapy with TLX250 as assessed by the tumours responding to the Telix therapy versus the current standard of care alone.
- TLX250 targets carbonic anhydrase IX (CA9),[1] a protein that is highly expressed in patients that are likely to demonstrate a more limited response to cancer immunotherapy.
- STARLITE 2 (NCT05239533) will assess the efficacy of TLX250 targeted radiation in combination with immunotherapy for clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer.
